On February 19, 2020, StageZero Life Sciences Ltd. (“StageZero”, or the “Company”) (TSXV: SZLS) announced the final closing of its non-brokered private placement offering of convertible debentures (each a “Debenture”) for gross proceeds of $1,180,000.
StageZero was represented by WeirFoulds LLP, with a team consisting of Rob Eberschlag, Aashima Singh (securities), Dan Thomson (financial services), and Claire Davis (articling student).
The Debentures, issued in increments of $1,000, bear interest at a rate of 6% per annum, have a term of 18 months from the date of issue and are convertible into units. Each Unit consists of one common share of the Company and one-half of a common share purchase warrant.
StageZero is a Canadian company which is focused on developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications.
WeirFoulds is pleased to have assisted StageZero in the transactions.
To learn more about our Securities Practice Group or to contact one of our securities lawyers, visit our securities practice group overview page.
